High-circulating Tie2 is associated with pathologic complete response to chemotherapy and antiangiogenic therapy in breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 39, Issue 3, 2016, Pages 248-254

  Makhoul, Issam ^a   Griffin, Robert J ^a   Siegel, Eric ^a   Lee, Jeannette ^a   Dhakal, Ishwori ^a   Raj, Vinay ^a   Jamshidi Parsian, Azemat ^a   Klimberg, Suzanne ^b   Hutchins, Laura F ^a   Kadlubar, Susan ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antiangiogenic therapy; Breast cancer; Neoadjuvant chemotherapy; Pathologic complete response; Tie2

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BEVACIZUMAB; CD31 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HORMONE RECEPTOR; INTERLEUKIN 1ALPHA; PLASMA PROTEIN; PLATELET DERIVED GROWTH FACTOR BB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGPT1 PROTEIN, HUMAN; ANGPT2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BECAPLERMIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; IL1A PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PROGESTERONE RECEPTOR; TAXOID; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AFRICAN AMERICAN; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; HISPANIC; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMISTRY; CLINICAL TRIAL; FEMALE; METABOLISM; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-1ALPHA; MATRIX METALLOPROTEINASE 9; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, ERBB-2; RECEPTOR, TIE-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84894372582     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000046     Document Type: Article

References (28)

1. Rugo HS Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist. 2004;9(SUPPL. 1):43-49.
2. Anan K, Morisaki T, Katano M, et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery. 1996; 119:333-339.
3. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86-91.
4. Yoshiji H, Gomez DE, Shibuya M, et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996;56:2013-2016.
5. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57:963-969.
6. Lee AH, Dublin EA, Bobrow LG, et al. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol. 1998;185:394-401.
7. Li CY, Shan S, Huang Q, et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 2000;92:143-147.
8. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol. 2005;23:1782-1790.
9. Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995;95:1789-1797.
10. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
11. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52:237-268.
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
15. Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol. 2010;2010:132641.
16. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290:H547-H559.
17. Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575-585.
18. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res. 2006;312:630-641.
19. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
20. Makhoul I, Klimberg VS, Korourian S, et al. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am J Clin Oncol. 2013. [Epub ahead print].
21. von Minckwitz G. Neoadjuvant therapy: what are the lessons so far? Hematol Oncol Clin North Am. 2013;27:767-784.
22. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30:2119-2127.
23. Ensembl A. Tie2. 2013. Available at: http://Apr2013.archive.ensembl.org/Homo-sapiens/Transcript/ProteinSummary?db=core;g=ENSG00000120156;r=9:27109139-27230173;t=ENST00000519097. Accessed May 11, 2013.
24. Findley CM, Mitchell RG, Duscha BD, et al. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol. 2008;52: 387-393.
25. Singh N, Macnamara E, Rashid S, et al. Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun. 2005;332:194-199.
26. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310-320.
27. von Minchwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299-309.
28. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2:416-422.